Cartesian Therapeutics (NASDAQ:RNAC) vs. Beyond Air (NASDAQ:XAIR) Head-To-Head Survey

Cartesian Therapeutics (NASDAQ:RNAC) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Cartesian Therapeutics and Beyond Air, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1	0	4	0	2.60
Beyond Air	1	0	1	1	2.67

Cartesian Therapeutics presently has a consensus target price of $38.00, suggesting a potential upside of 468.86%. Beyond Air has a consensus target price of $11.00, suggesting a potential upside of 1,362.38%. Given Beyond Air’s stronger consensus rating and higher possible upside, analysts plainly believe Beyond Air is more favorable than Cartesian Therapeutics.

Profitability

This table compares Cartesian Therapeutics and Beyond Air’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	N/A	N/A	-11.95%
Beyond Air	-632.51%	-261.08%	-119.07%

Volatility & Risk

Cartesian Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Beyond Air has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Institutional & Insider Ownership

86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 19.4% of Beyond Air shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Cartesian Therapeutics and Beyond Air”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$1.09 million	159.22	-$77.42 million	($1.56)	-4.28
Beyond Air	$5.80 million	1.04	-$46.62 million	($7.58)	-0.10

Beyond Air has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.

Summary

Cartesian Therapeutics beats Beyond Air on 9 of the 15 factors compared between the two stocks.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

About Beyond Air

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.